Esther Schachter-Tokarz

Montefiore Medical Center — United States

Medicine · Health Sciences

4h-index191citations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(11), Retinoids in leukemia and cellular processes(11), Acute Lymphoblastic Leukemia research(5), Advanced biosensing and bioanalysis techniques(1), HIV/AIDS drug development and treatment(1)

Publications11 total

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia
Blood·2012· 54 citedOpen Access
Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.
Blood·2010
Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
Journal of Clinical Oncology·2010· 88 citedOpen Access
PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
Leukemia·2009· 16 cited
Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.
Blood·2008
Uncommon Mutations in PML-RARα Associated with Poor Outcome after First Relapse in APL.
Blood·2007
Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.
Blood·2006· 2 cited
Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.
Blood·2006· 1 cited
PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia (APL)
Journal of Clinical Oncology·2006· 3 cited
Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure
Leukemia·2006· 27 citedOpen Access
Assessment of Minimal Residual Disease (MRD) by Qualitative RT-PCR (Q-PCR) vs Real-Time Quantitative RT-PCR (RQ-PCR) in a Phase II Study of Acute Promyelocytic Leukemia (APL).
Blood·2005

Frequent Co-authors

Robert E. Gallagher(11), Barry Kurt Moser(5), Martin S. Tallman(5), Richard A. Larson(5), Bayard L. Powell(5), Cheryl L. Willman(5), Wendy Stock(5), Clara D. Bloomfield(4), Richard C. Harvey(4), Frederick R. Appelbaum(4), Dorie A. Sher(3), James H. Feusner(3), Elisabeth Paietta(3), Steven D. Gore(2), Ivana Gojo(2), Mikkael A. Sekeres(2), Lawrence E. Morris(2), Marcel P. Devetten(2), Katarzyna Jamieson(2), Robert L. Redner(2)